%0 Journal Article
%T Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial.
%A Tavares CAM
%A Azevedo LCP
%A Rea-Neto Á
%A Campos NS
%A Amendola CP
%A Kozesinski-Nakatani AC
%A David-João PG
%A Lobo SM
%A Filiponi TC
%A Almeida GMB
%A Bergo RR
%A Guimarães-Júnior MRR
%A Figueiredo RC
%A Castro JR
%A Schuler CJ
%A Westphal GA
%A Carioca ACR
%A Monfradini F
%A Nieri J
%A Neves FMO
%A Paulo JA
%A Albuquerque CSN
%A Silva MCR
%A Kosiborod MN
%A Pereira AJ
%A Damiani LP
%A Corrêa TD
%A Serpa-Neto A
%A Berwanger O
%A Zampieri FG
%A  
%J JAMA
%V 332
%N 5
%D 2024 08 6
%M 38873723
%F 157.335
%R 10.1001/jama.2024.10510
%X Sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve outcomes in patients with type 2 diabetes, heart failure, and chronic kidney disease, but their effect on outcomes of critically ill patients with organ failure is unknown.<BR>To determine whether the addition of dapagliflozin, an SGLT-2 inhibitor, to standard intensive care unit (ICU) care improves outcomes in a critically ill population with acute organ dysfunction.<BR>Multicenter, randomized, open-label, clinical trial conducted at 22 ICUs in Brazil. Participants with unplanned ICU admission and presenting with at least 1 organ dysfunction (respiratory, cardiovascular, or kidney) were enrolled between November 22, 2022, and August 30, 2023, with follow-up through September 27, 2023.<BR>Participants were randomized to 10 mg of dapagliflozin (intervention, n = 248) plus standard care or to standard care alone (control, n = 259) for up to 14 days or until ICU discharge, whichever occurred first.<BR>The primary outcome was a hierarchical composite of hospital mortality, initiation of kidney replacement therapy, and ICU length of stay through 28 days, analyzed using the win ratio method. Secondary outcomes included the individual components of the hierarchical outcome, duration of organ support-free days, ICU, and hospital stay, assessed using bayesian regression models.<BR>Among 507 randomized participants (mean age, 63.9 [SD, 15] years; 46.9%, women), 39.6% had an ICU admission due to suspected infection. The median time from ICU admission to randomization was 1 day (IQR, 0-1). The win ratio for dapagliflozin for the primary outcome was 1.01 (95% CI, 0.90 to 1.13; P = .89). Among all secondary outcomes, the highest probability of benefit found was 0.90 for dapagliflozin regarding use of kidney replacement therapy among 27 patients (10.9%) in the dapagliflozin group vs 39 (15.1%) in the control group.<BR>The addition of dapagliflozin to standard care for critically ill patients and acute organ dysfunction did not improve clinical outcomes; however, confidence intervals were wide and could not exclude relevant benefits or harms for dapagliflozin.<BR>ClinicalTrials.gov Identifier: NCT05558098.